Is Marksans Pharma Ltd (MARKSANS) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Marksans Pharma Ltd is a average quality company .

Is Marksans Pharma Ltd (MARKSANS) undervalued or overvalued?

The key valuation ratios of Marksans Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Marksans Pharma Ltd (MARKSANS) share price return in the past 10 years?

Marksans Pharma Ltd share price has appreciated 14.5% annually (CAGR) over the past ten years.

Is Marksans Pharma Ltd (MARKSANS) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Marksans Pharma Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Marksans Pharma Ltd (MARKSANS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Marksans Pharma Ltd (MARKSANS) on 17-Apr-2026 16:59:59 at 16:59 is 179.55.

What is the P/E ratio of Marksans Pharma?

The latest standalone P/E ratio of Marksans Pharma as of 17-Apr-2026 is 33.03.

What is the P/B ratio of Marksans Pharma Ltd (MARKSANS)?

The latest standalone P/B ratio of Marksans Pharma Ltd (MARKSANS) as of 17-Apr-2026 is 5.23.

What is the 52-week high and low of Marksans Pharma Ltd (MARKSANS)?

The 52-week high of Marksans Pharma Ltd (MARKSANS) is Rs. 270.60 and the 52-week low is Rs. 156.00.

Marksans Pharma Ltd (MARKSANS) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Marksans Pharma Ltd (MARKSANS)
Brand: Marksans Pharma

Marksans Pharma Ltd (MARKSANS) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Marksans Pharma Ltd (MARKSANS)

BSE: 524404 NSE: MARKSANS

Key Metrics

Market Cap

₹8,137 Cr.

P/E Ratio

33.03

Price to Book (P/B)

5.23

Price to Sales (P/S)

6.36

EV/EBITDA

22.36

Return on Capital Employed (ROCE)

18.76%

Current Price

₹179.6

Return on Equity (ROE)

14.45%

Return on Assets (ROA)

11.26%

Operating Profit Margin

17.7%

Net Profit Margin

16.03%

Gross Profit Margin

23.1%

Book Value per Share

₹34.3

Sales Growth (YoY)

37.63%

Sales Growth (3 Years)

21.28%

Operating Profit Growth (1 Year)

45.81%

Operating Profit Growth (3 Years)

21.52%

Net Profit Growth (1 Year)

40.75%

52-Week Low / High

₹156 / 271

Net Profit Growth (3 Years)

21.88%

Dividend Yield

0.36%

Promoter Holding

43.87%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Marksans Pharma Ltd?

Marksans Pharma Ltd revenue growth is 37.6% for FY-2025 , which is above its 5 year CAGR of 22.1% , indicating faster growth.

Q.1 Promoter shareholding and pledge status of Marksans Pharma Ltd?

Promoters hold 43.87% of the Marksans Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Marksans Pharma Ltd vs industry peers?

Marksans Pharma Ltd revenue CAGR is 22.06% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.

Q.1 Which industry/sub-sector does Marksans Pharma Ltd belong to?

Marksans Pharma Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Marksans Pharma Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 14.4% based on the current price.

DeciZen - make an informed investing decision on Marksans Pharma

Based on:

Data

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation

3. Price Trend

Marksans Pharma stock performance

Key Ratios

Is Marksans Pharma Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	22.5%	3.4%	4.9%	12%	11.4%	23.5%	19.9%	14.3%	14.8%	18.8%	-
Value Creation Index ⓘ	0.6	-0.8	-0.7	-0.1	-0.2	0.7	0.4	0.0	0.1	0.4	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	358	216	295	424	433	600	658	655	853	1,174	1,279
Sales YoY Gr.	-	-39.7%	36.5%	44%	2.2%	38.3%	9.8%	-0.5%	30.2%	37.6%	-
Adj EPS ⓘ	1.7	0.1	0.2	1	0.9	2.4	2.2	1.8	2.8	3.9	5.4
YoY Gr.	-	-94%	80%	450%	-6.1%	160.2%	-9.5%	-16.4%	54.1%	36.5%	-
BVPS (₹) ⓘ	10	10.2	10.5	11.5	12.4	14.7	16.9	24.5	27	30.5	34.3
Adj Net Profit ⓘ	68.3	3.9	7.3	40.7	37.9	99.1	89.5	83.1	128	175	247
Cash Flow from Ops. ⓘ	64.8	-13.6	15.6	19.8	108	107	56	51.7	34.1	31	-
Debt/CF from Ops. ⓘ	0.6	-5.4	4.3	3.9	0	0	0.1	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	14.1%	22.1%	21.3%	37.6%
Adj EPS ⓘ	9.7%	32.9%	20.7%	36.5%
BVPSⓘ	13.2%	19.8%	21.8%	13.2%
Share Price	14.5%	27.5%	32.4%	-15.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	17.5	0.9	1.7	9	7.8	17.9	12.9	8.8	11	13.4	16.8
Op. Profit Mgn % ⓘ	27.8	6.3	9.9	14.9	16.5	19.1	17.3	12.8	16.4	17.7	21
Net Profit Mgn % ⓘ	19.1	1.8	2.5	9.6	8.8	16.5	13.6	12.7	15	14.9	19.3
Debt to Equity ⓘ	0.1	0.2	0.2	0.2	0	0	0	0	0	0	-
Working Cap Days ⓘ	206	352	278	223	227	165	187	238	253	240	161
Cash Conv. Cycle ⓘ	127	260	208	160	157	105	121	146	143	133	114

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	5.4	8
TTM Sales (₹ Cr.)	1,279	2,803
BVPS (₹) ⓘ	34.3	61.8
Reserves (₹ Cr.) ⓘ	1,511	2,756
P/BV ⓘ	5.23	2.90
PE ⓘ	33.03	22.58

From the Market
52 Week Low / High (₹)	156.00 / 270.60
All Time Low / High (₹)	0.70 / 358.50
Market Cap (₹ Cr.)	8,137
Equity (₹ Cr.)	45.3
Face Value (₹)	1
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Marksans Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	358	216	295	424	433	600	658	655	853	1,174
Operating Expenses ⓘ +	259	202	266	361	362	486	545	582	713	970
Manufacturing Costs	22	19	19	21	18	23	17	40	72	95
Material Costs	178	112	169	236	245	338	378	394	479	640
Employee Cost	26	40	46	46	49	55	60	56	77	102
Other Costs ⓘ	33	31	32	57	50	70	90	91	85	133
Operating Profit ⓘ	99	14	29	63	71	114	114	73	140	204
Operating Profit Margin (%)	27.7%	6.3%	9.9%	14.9%	16.5%	19.0%	17.3%	11.1%	16.4%	17.4%
Other Income ⓘ +	13	18	7	8	0	31	42	79	62	70
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	6	4	8	7	7	5	4	4	1	1
Depreciation ⓘ	15	15	12	9	12	15	18	17	29	29
Profit Before Tax ⓘ	92	12	17	56	53	124	135	132	172	243
Tax ⓘ	20	0	4	12	15	26	31	29	38	55
Profit After Tax	71	12	12	44	38	98	104	103	134	188
PAT Margin (%)	20.0%	5.4%	4.2%	10.3%	8.8%	16.4%	15.8%	15.7%	15.7%	16.0%
Adjusted EPS (₹)	1.8	0.3	0.3	1.1	0.9	2.4	2.5	2.3	3.0	4.2
Dividend Payout Ratio (%)	7%	18%	16%	5%	11%	10%	10%	22%	20%	19%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	423	419	429	471	506	600	692	1,111	1,223	1,383
Share Capital ⓘ	53	41	41	41	41	41	41	45	45	45
Reserves ⓘ	369	378	388	430	465	559	651	1,066	1,177	1,338
Debt +	41	73	66	77	0	0	5	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	41	73	66	77	0	0	5	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	31	21	34	37	57	64	74	112	160	204
Others Liabilities ⓘ	39	33	31	40	48	97	218	146	166	209
Total Liabilities ⓘ	534	546	560	625	610	761	989	1,369	1,548	1,796
Fixed Assets
Net Fixed Assets ⓘ +	97	94	88	103	115	129	136	144	272	383
Gross Block	184	196	202	225	249	277	301	319	414	555
Accumulated Depreciation	87	102	114	122	134	148	166	175	143	172
CWIP ⓘ	0	0	0	0	0	0	0	4	0	0
Investments ⓘ	231	234	236	236	236	236	237	266	293	266
Inventories	44	29	42	70	75	94	104	131	191	205
Trade Receivables	133	155	169	178	162	169	247	305	370	550
Cash Equivalents	3	3	1	2	3	106	224	440	312	269
Others Assets ⓘ	25	31	24	36	19	27	43	78	111	123
Total Assets ⓘ	534	546	560	625	610	761	989	1,369	1,548	1,796

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	65	-14	16	20	108	107	56	52	34	31
PBT ⓘ	92	12	17	56	53	124	135	132	172	243
Adjustment ⓘ	9	13	20	12	19	-9	-8	11	-16	-8
Changes in Working Capital ⓘ	-15	-22	-16	-35	46	12	-39	-60	-83	-158
Tax Paid ⓘ	-20	-16	-5	-13	-10	-20	-32	-32	-39	-47
Cash Flow From Investing Activity ⓘ +	-177	-8	-8	-20	-24	9	-128	-195	-114	17
Capex	-22	-12	-6	-23	-24	-21	-23	-35	-155	-120
Net Investments	-164	-3	-2	0	0	0	-120	-149	-4	89
Others ⓘ	9	7	0	3	0	29	15	-10	45	48
Cash Flow From Financing Activity ⓘ +	-52	21	-10	1	-82	-14	71	210	-26	-30
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-3	-4	-8	-7	-7	-5	-3	-4	0	0
Dividend Paid ⓘ	-7	-6	-2	-2	-2	-4	-11	-10	-23	-27
Others ⓘ	-42	31	0	10	-72	-4	85	224	-4	-3
Net Cash Flow ⓘ	-164	-1	-2	1	2	102	-1	67	-106	18

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	18.91	2.79	2.93	9.7	7.77	17.8	16.11	11.41	11.46	14.45
ROCE (%)	22.45	3.44	4.92	11.99	11.39	23.46	19.91	14.27	14.81	18.76
Asset Turnover Ratio	0.67	0.4	0.53	0.72	0.7	0.88	0.76	0.59	0.59	0.7
PAT to CFO Conversion(x)	0.92	-1.17	1.33	0.45	2.84	1.09	0.54	0.5	0.25	0.16
Working Capital Days
Receivable Days	132	244	200	149	143	100	114	145	144	142
Inventory Days	48	62	44	48	61	51	54	62	69	61
Payable Days	78	84	59	55	70	65	67	86	103	104

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Marksans Pharma Ltd FAQs

The current trading price of Marksans Pharma on 17-Apr-2026 16:59 is ₹179.6.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Marksans Pharma stood at ₹8,136.6 Cr

The latest P/E ratio of Marksans Pharma as of 16-Apr-2026 is 33.03.

The latest P/B ratio of Marksans Pharma as of 16-Apr-2026 is 5.23.

The 52-week high of Marksans Pharma is ₹270.6 and the 52-week low is ₹156.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Marksans Pharma is ₹1,279 ( Cr.) .

About Marksans Pharma Ltd

Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005.

Currently the company has presence in Active Pharmaceuticals Ingredients (APIs), formulations and biopharmaceuticals. It is also actively engaged in research and development and offers contract research and manufacturing services (CRAMS) to global pharmaceutical companies.

The company, engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.

The company's plants have been built as per USFDA guidelines and have received approval from various health authorities namely TGA (Australia), MHRA (United Kingdom) ANVISA (Brazil) apart from WHO GMP certificate.

Marksans Pharma acquired Relonchem, a leading UK-based generic pharmaceutical company. This acquisition gave company an immediate sales and marketing front-end access to the highly regulated and lucrative generic medicines market in UK and Europe.

Marksans Pharma exports its products to markets in Europe, Latin America, Africa and Oceania.

In 2010 Company entered into a Business Transfer Agreement with Kores (India) Limited

Business area

Research and Development- The companyâ€™s R&D centre is situated in Goa and is engaged in new drug discovery chemistry, pharmacokinetics, pharmacology/ molecular biology, toxicology, and related skills and support areas.

Formulation- This division is engaged in manufacturing of tablets, non-sterile liquids, ointments and powder products. The company owns one of the biggest manufacturing facility for soft gelatin in Asia. The companyâ€™s manufacturing plants are located at Goa and UK.

APIs- Marksans' two APIs manufacturing units are located in Pune. The present manufacturing capacity of 1140 TPA that comprises of 600 TPA Quinolones, 360 TPA Ranitidine, and 180 others.

CRAMS- The company has alliances with the top 8 MNC generic companies for contract manufacturing of 30 generic products for the European markets. It has entered into licensing agreements with numerous companies for development and supply of products for 7-10 years.

Milestones

2009 - Marksans Pharma establlished itself as a global player
2008 - Acquired Bells, Sons & Co. (Druggists) Ltd.
Acquired Relonchem Limited
2005 - Acquired Nova Pharmaceuticals Australasia Pty Ltd.
2003 - Spun-off into a separate entity - Glenmark Laboratories Ltd.
Changed its name to "Marksans Pharma Ltd"
2001 - Marksans was incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Marksans Pharma Ltd (MARKSANS) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Marksans Pharma Share Price